Immunosens
Funding Series
Series B-2 *July 26th 2023
Funding Amount
¥100m
[data from INITIAL 2024 Dec]
Aging Tech Healthcare/Medtech

About

This startup from Osaka University aims to create a healthy, long-lived society where anyone can enjoy medical-grade rapid testing anytime a​nd anywhere using GLEIA, a unique immunoassay technology.

Milestone

Immunosense plans to launch a healthcare product in 2025 by applying an immunoassay device for POCT developed using its unique GLEIA method. To aid in its expansion, they are currently obtaining medical certification.
Visit Site
We're Here to Help
Have questions? Not sure where to start? Send us an email and let’s chat!
Email Us
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.